DDInter904 DDInter740
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Idarubicin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Idarubicin {u} (Compound) downregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Idarubicin {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Idarubicin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Idarubicin {u} (Compound) downregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Idarubicin {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Idarubicin {u} (Compound) downregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is regulated by {v} (Gene) PHGDH
PHGDH {u} (Gene) is upregulated by {v} (Compound) Flecainide
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Idarubicin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Idarubicin (Compound) downregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Idarubicin (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Idarubicin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Idarubicin (Compound) downregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Idarubicin (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Idarubicin (Compound) downregulates HMOX1 (Gene) and HMOX1 (Gene) is regulated by PHGDH (Gene) and PHGDH (Gene) is upregulated by Flecainide (Compound)